We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Coagulation Test Correlates Protein Concentration for Plasma Cell Dyscrasia

By LabMedica International staff writers
Posted on 07 Jan 2013
Abnormal screening coagulation tests are frequently observed in asymptomatic patients with multiple myeloma and other plasma cell neoplasms. More...


Prothrombin time (PT), activated partial thromboplastin time (APTT) and fibrinogen activity have been linked with clinical history and disease parameters in patients with plasma cell dyscrasia.

Scientists at the University of Arkansas for Medical Sciences (Little Rock, AR, USA) studied coagulation tests in a total of 252 patients. Of these, 79 patients (31%) had abnormal routine screening coagulation test results. An isolated prolonged PT of greater than 15 seconds was found in 62 patients (25%), and 10 patients had prolonged PT and APTT (4%).

Prothrombin time, APTT, and fibrinogen activity were analyzed on the STA-R Evolution, using PT reagent Neoplastine CI PLUS and APTT reagent STA-PTT A, all products of Diagnostica Stago (Parsippany, NJ, USA). Fibrinogen activity was determined by measuring the clotting time of diluted plasma in the presence of excess thrombin with a reference range of 197–447 mg/dL. The quantitation of monoclonal proteins was performed by separating serum proteins using capillary electrophoresis with direct protein detection by UV absorbance at 200 nm.

An isolated prolonged PT was the most common abnormal coagulation test found in 25% of the patients. A prolonged PT was more frequently observed in 157patients with the multiple myeloma compared to the 34 monoclonal gammopathy of undetermined significance (MGUS) patients or other diagnostic categories of plasma cell dyscrasia. There were no differences immunoglobulin isotype in 62 patients with isolated prolonged PT compared to the 173 patients with normal screening coagulation tests. Fibrinogen activity was significantly lower in patients with prolonged PT although there was no correlation between fibrinogen activity and PT. Serum M protein concentrations were significantly greater in patients with prolonged PT and were positively correlated with PT. Serum M protein concentrations were significantly elevated in patients with prolonged PT compared to patients with normal PT and were positively correlated with PT values.

The authors concluded that there was an association between disease severity and prolonged PT in that patients with multiple myeloma were more likely to have prolonged PT than patients with other plasma cell neoplasms. Of the factors examined, the monoclonal protein level was significantly higher in patients with isolated prolonged PT and correlated with PT. The study was published on December 7, 2012, in the International Journal of Laboratory Hematology.

Related Links:
University of Arkansas for Medical Sciences
Diagnostica Stago


New
Gold Member
Clinical Drug Testing Panel
DOA Urine MultiPlex
POC Helicobacter Pylori Test Kit
Hepy Urease Test
8-Channel Pipette
SAPPHIRE 20–300 µL
Rapid Molecular Testing Device
FlashDetect Flash10
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: Senior researcher Annikka Polster collaborated with Nicola Pietro Montaldo in discovering the Parkinson’s Biomarkers (Photo courtesy of Chalmers University of Technology)

Newly-Identified Parkinson’s Biomarkers to Enable Early Diagnosis Via Blood Tests

Parkinson’s disease is a slow-progressing neurological disorder that disrupts the brain’s ability to control movement and is typically diagnosed after the age of 55. By the time motor symptoms appear,... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Noul’s AI-based cervical cancer diagnostic solution, miLab CER (Photo courtesy of Noul)

AI-Powered Cervical Cancer Test Set for Major Rollout in Latin America

Noul Co., a Korean company specializing in AI-based blood and cancer diagnostics, announced it will supply its intelligence (AI)-based miLab CER cervical cancer diagnostic solution to Mexico under a multi‑year... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.